General Information
Drug ID
DR00182
Drug Name
Dasatinib
Synonyms
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide; BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE; N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; SPRYCEL (TN); Sprycel; Spyrcel
Drug Type
Small molecular drug
Indication Multiple myeloma [ICD11: 2A83] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C22H26ClN7O2S
Canonical SMILES
CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
InChI
InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
InChIKey
ZBNZXTGUTAYRHI-UHFFFAOYSA-N
CAS Number
CAS 302962-49-8
Pharmaceutical Properties Molecular Weight 488 Topological Polar Surface Area 135
Heavy Atom Count 33 Rotatable Bond Count 7
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 9
XLogP
3.6
PubChem CID
3062316
PubChem SID
10061134 , 103501621 , 103905543 , 111644212 , 117418208 , 117695728 , 118050493 , 119503515 , 12015788 , 124361516 , 124756940 , 124893650 , 124893651 , 124893652 , 125001912 , 125163747 , 125264620 , 125347447 , 126624063 , 14859389 , 17397755 , 17422520 , 36127155 , 46505143 , 46513626 , 47883136 , 48429642 , 49742622 , 50070229 , 50070567 , 50071309 , 50100097 , 50125840 , 52995488 , 53799228 , 56312240 , 56312839 , 56313127 , 56373968 , 56459420 , 57288451 , 57354110 , 57551950 , 74374210 , 85246174 , 87235888 , 87357382 , 93581026 , 99381604 , 99437986
ChEBI ID
ChEBI:49375
TTD Drug ID
D0E6XR
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [3]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
References
1 Dasatinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
3 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
4 Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.